Prosecution Insights
Prosecution Insights
6 pending office actions • 4 art units • 6 examiners • 0 of 6 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (17%) |
| §112 only | 2 (33%) |
| Double-patenting + other | 2 (33%) |
| Multi-statute (no §101) | 1 (17%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| CUNNINGCHEN, KATHLEEN MARY | 1 | 60.4% | +64.8% |
| GURLEY, JAMI MICHELLE | 1 | 54.2% | +14.3% |
| STOICA, ELLY GERALD | 1 | 66.8% | +22.7% |
| OGUNBIYI, OLUWATOSIN A | 1 | 63.7% | +41.5% |
| SKELDING, ZACHARY S | 1 | 59.8% | +41.0% |
| KIM, YUNSOO | 1 | 65.8% | +34.8% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18268746 | STABLE ANTIBODY FORMULATION, PREPARATION METHOD THEREFOR, AND APPLICATIONS THEREOF | GURLEY, JAMI MICHELLE | 32d overdue |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 6 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18268746 | STABLE ANTIBODY FORMULATION, PREPARATION METHOD THEREFOR, AND APPLICATIONS THEREOF | GURLEY, JAMI MICHELLE | 32d overdue |
| 18681485 | USE OF ANTI-PD-L1/CD47 BISPECIFIC ANTIBODY IN TREATMENT OF DISEASES | CUNNINGCHEN, KATHLEEN MARY | — |
| 18035591 | BISPECIFIC ANTIBODY AND USE THEREOF | STOICA, ELLY GERALD | — |
| 18007262 | ANTI-HER2 ANTIBODY AND USE THEREOF | OGUNBIYI, OLUWATOSIN A | — |
| 18045946 | LIQUID FORMULATION OF HUMANIZED ANTIBODY FOR TREATING IL-6-MEDIATED DISEASES | SKELDING, ZACHARY S | — |
| 17767990 | ANTI-CD20 ANTIBODY FORMULATION AND USE OF ANTI-CD20 ANTIBODY FOR TREATMENT OF CD20 POSITIVE DISEASES | KIM, YUNSOO | — |
| Art Unit | Apps |
|---|---|
| 1647 | 2 |
| 1645 | 1 |
| 1644 | 1 |
| 1641 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18681485 | USE OF ANTI-PD-L1/CD47 BISPECIFIC ANTIBODY IN TREATMENT OF DISEASES | CUNNINGCHEN, KATHLEEN MARY | — | §102§103§112DP | Non-Final OA | — | Pending | Feb 05, 2024 |
| 18268746 | STABLE ANTIBODY FORMULATION, PREPARATION METHOD THEREFOR, AND APPLICATIONS THEREOF | GURLEY, JAMI MICHELLE | 1647 | §102§103§112 | Non-Final OA | 32d overdue | Pending | Jun 21, 2023 |
| 18035591 | BISPECIFIC ANTIBODY AND USE THEREOF | STOICA, ELLY GERALD | 1647 | §112Other | Final Rejection | — | Pending | May 05, 2023 |
| 18007262 | ANTI-HER2 ANTIBODY AND USE THEREOF | OGUNBIYI, OLUWATOSIN A | 1645 | §103DPOther | Final Rejection | — | Pending | Jan 27, 2023 |
| 18045946 | LIQUID FORMULATION OF HUMANIZED ANTIBODY FOR TREATING IL-6-MEDIATED DISEASES | SKELDING, ZACHARY S | 1644 | §112 | Non-Final OA | — | Pending | Oct 12, 2022 |
| 17767990 | ANTI-CD20 ANTIBODY FORMULATION AND USE OF ANTI-CD20 ANTIBODY FOR TREATMENT OF CD20 POSITIVE DISEASES | KIM, YUNSOO | 1641 | §103 | Final Rejection | — | Pending | Apr 11, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial